坐骨神経痛の市場規模、シェア、成長分析：疾患タイプ別、薬剤クラス別、投与経路別、流通チャネル別、地域別 - 産業予測 2025～2032年

坐骨神経痛の世界市場規模は2023年に81億8,000万米ドルと評価され、2024年の86億5,000万米ドルから2032年には134億7,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは5.7％で成長する見通しです。

坐骨神経痛の世界市場は、座りがちなライフスタイル、人口動態の高齢化、脊椎疾患の急増に関連した坐骨神経痛症例の増加が主な要因となって、今後数年間で大幅な成長が見込まれています。診断技術や治療方法の革新により、診断精度と管理効果が向上しています。さらに、早期介入とリハビリテーションの必要性に対する意識の高まりが市場拡大を後押ししています。しかし、高額な治療費、地域によっては高度なヘルスケアシステムへのアクセスが制限されていること、外科手術に伴うリスクなどの課題も残っています。こうしたハードルにもかかわらず、低侵襲技術へのシフト、新しい治療薬のイントロダクション、個別化された治療ソリューションへの意欲の高まりが、世界の坐骨神経痛市場を活性化すると予想されます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• 技術評価
• 特許分析

坐骨神経痛市場規模：疾患タイプ別

• 市場概要
• 急性の坐骨神経痛
• 慢性の坐骨神経痛
• その他

坐骨神経痛市場規模：薬剤クラス別

• 市場概要
• 非ステロイド性抗炎症薬
• 経口ステロイド
• 抗けいれん薬
• 三環系抗うつ薬
• オピオイド鎮痛剤
• その他

坐骨神経痛市場規模：投与経路別

• 市場概要
• オーラル
• 注射

坐骨神経痛市場規模：流通チャネル別

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

坐骨神経痛市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

主要企業プロファイル

• Medtronic plc（Ireland）
• Johnson & Johnson（USA）
• Zimmer Biomet Holdings, Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Sanofi S.A.（France）
• Novartis International AG（Switzerland）
• Bristol-Myers Squibb Company（USA）
• Merck & Co., Inc.（USA）
• Zynex Inc.（USA）
• Sorrento Therapeutics, Inc（USA）
• Hikma Pharmaceuticals PLC（UK）
• Viatris Inc.（USA）
• Boston Scientific Corporation（USA）
• Abbott Laboratories（USA）
• Stryker Corporation（USA）
• GlaxoSmithKline plc（UK）
• AstraZeneca plc（UK）
• Eli Lilly and Company（USA）
• Bristol-Myers Squibb Company（USA）

結論と推奨事項

Global Sciatica Market size was valued at USD 8.18 billion in 2023 and is poised to grow from USD 8.65 billion in 2024 to USD 13.47 billion by 2032, growing at a CAGR of 5.7% during the forecast period (2025-2032).

The global sciatica market is poised for substantial growth in the upcoming years, primarily due to a rise in sciatica cases linked to sedentary lifestyles, an aging demographic, and a surge in spinal disorders. Innovations in diagnostic technologies and treatment options are enhancing diagnosis accuracy and management effectiveness. Furthermore, heightened awareness of the need for early intervention and rehabilitation is propelling market expansion. However, challenges persist, including high treatment costs, restricted access to advanced healthcare systems in some areas, and risks associated with surgical procedures. Despite these hurdles, the shift toward minimally invasive techniques, the introduction of new therapeutics, and a growing appetite for personalized treatment solutions are anticipated to invigorate the global sciatica market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Sciatica market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Sciatica Market Segmental Analysis

Global Sciatica Market is segmented by Disease Type, Drug Class, Route of Administration, Distribution Channel and region. Based on Disease Type, the market is segmented into Acute Sciatica, Chronic Sciatica and Others. Based on Drug Class, the market is segmented into Nonsteroidal Anti-Inflammatory Drugs, Oral Steroids, Anticonvulsant Agents, Tricyclic Antidepressants, Opioid Analgesics and Others. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Sciatica Market

A significant factor propelling the global sciatica market is the widespread lack of awareness and subsequent underdiagnosis of the condition. Contributing elements include sedentary lifestyles, poor posture, rising obesity rates, and an aging demographic, all of which have led to an increased prevalence of sciatica cases. As awareness grows and more individuals seek proper diagnosis and treatment, there is a heightened demand for effective diagnostic methods, therapeutic interventions, and pain management options. This growing need plays a crucial role in driving the overall expansion of the market and underscores the importance of addressing this overlooked health issue.

Restraints in the Global Sciatica Market

One significant challenge facing the global sciatica market is the prevalent lack of awareness and underdiagnosis associated with the condition. Many individuals experiencing sciatica symptoms are often unaware of their significance, which results in delayed medical intervention and treatment. Additionally, restricted access to healthcare services, particularly in rural regions, exacerbates the issue, restricting timely diagnosis and effective management of sciatica. Enhancing public knowledge about sciatica and improving healthcare infrastructure is crucial to alleviating this restraint. By fostering greater awareness and accessibility, the market can better serve individuals in need and contribute to improved health outcomes for sciatica patients.

Market Trends of the Global Sciatica Market

A prominent trend in the global sciatica market is the rising preference for minimally invasive procedures to address sciatic pain. Treatments such as endoscopic discectomy and percutaneous decompression are increasingly favored over traditional surgeries due to their numerous advantages, including smaller incisions, decreased tissue damage, and shortened recovery times. This shift is largely driven by patient demand for quicker rehabilitation and better overall outcomes, alongside a notable reduction in the risk of complications often associated with invasive surgeries. Consequently, both healthcare providers and patients are gravitating towards these innovative, less invasive options, significantly propelling growth in the global sciatica market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Technology Assessment
• Patent Analysis

Global Sciatica Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Acute Sciatica
• Chronic Sciatica
• Others

Global Sciatica Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Nonsteroidal Anti-Inflammatory Drugs
• Oral Steroids
• Anticonvulsant Agents
• Tricyclic Antidepressants
• Opioid Analgesics
• Others

Global Sciatica Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable

Global Sciatica Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Sciatica Market Size & CAGR (2025-2032)

• North America (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zimmer Biomet Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zynex Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sorrento Therapeutics, Inc (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stryker Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations